117 related articles for article (PubMed ID: 8778318)
21. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
22. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
23. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
24. CD40 expression in bladder cancer.
Cooke PW; James ND; Ganesan R; Wallace M; Burton A; Young LS
J Pathol; 1999 May; 188(1):38-43. PubMed ID: 10398138
[TBL] [Abstract][Full Text] [Related]
25. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
[TBL] [Abstract][Full Text] [Related]
26. May cathepsin D immunoreactivity be used as a prognostic factor in endometrial carcinomas? A comparative immunohistochemical study.
Saygili U; Koyuncuoglu M; Altunyurt S; Guclu S; Uslu T; Erten O
Gynecol Oncol; 2001 Oct; 83(1):20-4. PubMed ID: 11585409
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters.
Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Requena MJ; Montironi R
Am J Clin Pathol; 2004 Sep; 122(3):444-52. PubMed ID: 15362377
[TBL] [Abstract][Full Text] [Related]
28. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
May M; Nitzke T; Helke C; Vogler H; Hoschke B
Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
[TBL] [Abstract][Full Text] [Related]
29. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
Ma BB; Poon TC; To KF; Zee B; Mo FK; Chan CM; Ho S; Teo PM; Johnson PJ; Chan AT
Head Neck; 2003 Oct; 25(10):864-72. PubMed ID: 12966511
[TBL] [Abstract][Full Text] [Related]
31. The immunohistochemical detection of cripto-1 in benign and malignant human bladder.
Byrne RL; Autzen P; Birch P; Robinson MC; Gullick WJ; Neal DE; Hamdy FC
J Pathol; 1998 May; 185(1):108-11. PubMed ID: 9713367
[TBL] [Abstract][Full Text] [Related]
32. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.
Dalbagni G; Parekh DJ; Ben-Porat L; Potenzoni M; Herr HW; Reuter VE
BJU Int; 2007 Feb; 99(2):281-5. PubMed ID: 17155984
[TBL] [Abstract][Full Text] [Related]
33. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
Vasala K; Pääkko P; Turpeenniemi-Hujanen T
Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455
[TBL] [Abstract][Full Text] [Related]
35. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.
Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Syrjänen K; Kosma VM
Br J Cancer; 1999 Aug; 80(12):2001-7. PubMed ID: 10471053
[TBL] [Abstract][Full Text] [Related]
36. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
[TBL] [Abstract][Full Text] [Related]
37. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer.
Cardillo MR; Castagna G; Memeo L; De Bernardinis E; Di Silverio F
J Exp Clin Cancer Res; 2000 Jun; 19(2):225-33. PubMed ID: 10965823
[TBL] [Abstract][Full Text] [Related]
39. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
[TBL] [Abstract][Full Text] [Related]
40. Nerve growth factor receptor (p75 NTR) and pattern of invasion predict poor prognosis in oral squamous cell carcinoma.
Søland TM; Brusevold IJ; Koppang HS; Schenck K; Bryne M
Histopathology; 2008 Jul; 53(1):62-72. PubMed ID: 18540978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
